



## **Mersana to Participate in the BIO CEO & Investor Conference**

February 4, 2013

Mersana Therapeutics, a biopharmaceutical company developing its Fleximer® antibody-drug conjugate (ADC) platform and pipeline of small molecule Fleximer conjugates, today announced its participation in the upcoming 15th Annual BIO CEO & Investor Conference in New York City.

Dr. Nicholas G. Bacopoulos, President and Chief Executive Officer, is scheduled to present on Tuesday, February 12, 2013 at 10:30am in the Park South room at the Waldorf Astoria Hotel.

### **About Mersana**

Mersana engineers novel drug conjugates that maximize the potential of new and established therapeutic classes. Utilizing its proprietary conjugation technology, which is comprised of the Fleximer® polymer and a broad array of customizable linker chemistries, Mersana is developing its next-generation antibody-drug conjugate (ADC) platform with superior properties not found with other ADC technologies. Mersana is currently working with a number of top Pharma companies to develop next generation Fleximer-ADCs and most recently announced a \$270 million collaboration with Endo Pharmaceuticals in March, 2012. The company is also advancing its own pipeline of next-generation drugs with best-in-class potential to address unmet needs and improve patient outcomes in multiple oncology indications.

### **Media Contact**

MacDougall Biomedical Communications  
Kari Watson  
[781-235-3060](tel:781-235-3060)  
[kwatson@macbiocom.com](mailto:kwatson@macbiocom.com)